DGAP-News: Medios AG / Key word(s): Expansion/Real Estate
Medios AG: Additional production site enables tripling of production capacities
Berlin, 8 July 2020 – Medios AG (‘Company’), one of the leading Specialty Pharma companies in Germany, has signed a contract to rent a further building with a total area of around 4,500 m2 at an existing site in Berlin. The Company intends in particular to establish further laboratories for the manufacturing of patient-specific therapies there and to further optimize logistics. In addition, most of the operating activities of Medios are to be concentrated at this location. The aim is to further increase the operating efficiency of the Medios Group and to realize synergy effects by expanding production capacities and centralizing the operating business.
The Executive Board expects to move into the premises and gradually start up the laboratories in the second half of 2021. Depending on capacity utilization, the production capacities in the Patient-specific Therapies segment could thus be as much as tripled. In addition, new jobs are to be created for laboratory operations in the medium term. The manageable investment to set up the laboratories and logistics is expected to amount to a high single-digit million € amount and will be financed with part of the growth capital that the Company has raised on the capital market in recent months.
Manfred Schneider, CEO of Medios AG: ‘With new laboratories and the resulting significantly increased production capacities, we are perfectly positioned to generate additional organic growth. This is another important step in positioning ourselves as the most innovative Specialty Pharma company in Germany.’
Matthias Gärtner, CFO of Medios AG: ‘The extensive centralization of most of our operational activities at one site enables us to further optimize manufacturing processes and logistics. This gives us the opportunity to realize high synergy effects at manageable costs.’
By concentrating production, warehousing and logistics at this site, the number of operating facilities in Berlin will be further reduced to three. The administrative units are already consolidated in the new premises in Berlin-Mitte since May 2020. The laboratory facilities in Berlin-Tempelhof will continue to be operated and will also serve as a fallback solution within the Medios Group.
About Medios AG
Medios AG is Germany’s first publicly listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8, DE000A288821) are listed in the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 30 232 566 – 800|
|Fax:||+49 30 232 566 – 801|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf|
|EQS News ID:||1080719|
|End of News||DGAP News Service|